Experimental anti-arrhythmic properties of melperone, a neuroleptic butyrophenone.
The neuroleptic butyrophenone, melperone, has been compared with antiarrhythmics, neuroleptics, alpha-blockers and beta-blockers in various experimental arrhythmias. Melperone 0.01--1 mg/kg intravenously antagonized ouabain-induced arrhythmias in conscious rabbits to the same degree as propranolol 2 mg/kg and quinidine 10 mg/kg intravenously probably mainly via s CNS depressive effect. It was found to be considerably weaker than propranolol 2 mg/kg, when anaesthetized guinea pigs were used. Melperone 0.1--10 mg/kg was inactive against aconitine-induced arrhythmias. Melperone 1--5 mg/kg antagonized adrenaline-induced arrhythmias in halothane-sensitized guinea pigs like phentolamine 1--5 mg/kg intravenously and was more potent than chlorpromazine, propranolol and quinidine. This study and an electrophysiological study suggest that melperone might be a type III anti-arrhythmic drug, which at the same time depresses CNS and reduces afterload.
D000157:Aconitine; D000818:Animals; D000889:Anti-Arrhythmia Agents; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy; D002090:Butyrophenones / Q000627:therapeutic use*; D004329:Droperidol / Q000627:therapeutic use; D004837:Epinephrine; D006168:Guinea Pigs; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D010042:Ouabain; D010880:Piperidines / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats
D000889:Anti-Arrhythmia Agents; D002090:Butyrophenones; D010880:Piperidines; D010042:Ouabain; D008012:Lidocaine; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide; D004329:Droperidol; D000157:Aconitine; D004837:Epinephrine